


PHARMACEUTICAL 2018

Cellectar Biosciences Inc. Rank 297 of 349





Cellectar Biosciences Inc. Rank 297 of 349

The relative strengths and weaknesses of Cellectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cellectar Biosciences Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Cellectar Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 353% points.

The company's Economic Capital Ratio, given in the ranking table, is -577%, being 299% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	10,939
Cost of Goods Sold	0
Intangible Assets	1,675
Liabilities, Current	2,115
Liabilities, Non-Current	2.2
Other Assets	12
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	39
Property and Equipment	245
Research and Development	9,466
Revenues	0
Selling, General and Administrative Expense	4,135

Output Variable	Value in 1000 USD
Assets	12,871
Liabilities	2,117
Expenses	13,601
Stockholders Equity	10,754
Net Income	-13,562
Comprehensive Net Income	-13,562
Economic Capital Ratio	-577%

